Discovery of a peptide proteolysis-targeting chimera (PROTAC) drug of p300 for prostate cancer therapy

Selective p300 degradation via peptide PROTAC: a new therapeutic strategy for advanced prostate cancers

“…reported the first peptide-based PROTAC targeting p300 via its CH1 domain. 10 Peptide drugs offer advantages in increased specificity and efficacy due to their capacity for larger interacting surfaces with binding partners. The peptide p300 PROTAC reported by Zhang et al.…”